Find out more about our ongoing work!


Dear all,

just before your well-deserved summer break, COPE is pleased to share some more news on our project's progress. June and July have been particularly exciting months for us with the very first presentation of preliminary data by David Nasralla on behalf of all involved in the WP2 liver trial at the American Transplant Congress in Boston. Congratulations to the entire WP2 team for this important and successful milestone! A further presentation will follow in August at the TTS in Hong Kong and the WP2 team is working hard towards a publication in the autumn of this year. 

COPE POMP and COPE COMPARE continue recruiting at a steady pace and we are pleased to soon welcome our new cooperating sites to the POMP trial namely the Charite Berlin (DE), the Semmelweis University in Budapest (HU), UCL in Brussels (BE) and the Hammersmith and Royal Free Hospitals in London (UK). Furthermore, we have submitted our second amendment request towards the EU Commission to extend COPE's duration by an additional year until June 2018. Naturally, we will keep you posted of this process. 

Do you want to find out more about our activities over the last two months? Just scroll down and enjoy the read!

With best wishes,

WP2 - Normothermic machine perfusion trial

  • We are very pleased to announce that preliminary data from the WP2 liver trial was presented at the American Transplant Congress in Boston (USA) in June 2016.
  • A further presentation will follow at The Transplantation Society Congress in Hong Kong in August 2016.
  • The WP2 team is working hard towards a publication in the autumn of this year once the 6-months follow-up time point is reached for all patients.
  • For WP2, a total of 25 research proposals has been received up until now including core research questions to be answered within the grant as well as ancillary studies raising new research ideas. The COPE office, WP2 team, biobank team as well as the respective Lead Authors are in discussion to ensure the correct set of data and samples can be identified for the research questions raised. 

WP3 - POMP Trial: oxygenated HMP re-conditioning of ECD kidneys

  • As of 4 July 2016, POMP randomised 102 kidneys. 
  • For our new Hungarian partner, Semmelweis University in Budapest, all required documentation for Ethical approval have been submitted and the Ethics Committee met on 28 June 2016. We are thrilled to announce that POMP has achieved Ethical approval in Hungary on 11 July 2017. We are now finalizing the sponsorship agreement between Oxford, Essen and Budapest and we are currently arranging the logistical set-up of this new site.  
  • For the Royal Free Hospital and the Hammersmith Hospital, a new Health Research Authority process has to be followed prolonging the time needed for the required R&D approvals. The COPE team and our partners at the Royal Free and Hammersmith are working hard to start POMP at these two new centres. 
  • Our new Belgian partner UCL Brussels can go live shortly. 
Prof Ploeg during kidney implant surgery

WP4 - COMPARE Trial: oxygenated HMP of DCD +50y kidneys

  • As of 8 July 2016,  174 donors were screened for the COPE COMPARE trial in The Netherlands and Belgium. Of these, 128 donors were assessed and 104 kidney pairs were randomized. 
  • Currently, 56 transplanted kidney pairs are active in the trial.
  • WP4 is furthermore in the process of entering sample data into the now fully functioning WP4 database. The UK Transplant Technicians are working with the filled sample worksheets to ensure all sample information is complete. 

WP5 & WP6 - Experimental work programmes

  • no current updates

WP7 - Biobank

  • A sample shipment was received from our Continental partners end of June 2016. With this shipment, all WP2 liver samples are now complete in Oxford. 
  • WP7 has furthermore prepared for our new POMP sites to come on board including shipment arrangements for Berlin and Budapest as well as additions to the POMP and biobank databases. 
  • All formalin-fixed samples are now embedded in paraffin blocks ready for slides to be created. 
  • Together with the WP2 team, we have furthermore identified the liver sample sets needed for our core research deliverable within the EU grant. These samples are now flagged in the biobank database to ensure they are available for when the analysis starts.  

WP8 - Trial design and methodology

  • The last Data Monitoring Committee meeting took place on 4 July 2016 in Oxford to discuss the progress of all COPE trials. 
  • Furthermore, WP8 has embarked on the first steps of the Health Economics Analysis in WP2 setting out the baseline data and creating the analysis plan. The full analysis will take place once the one-year data follow-up is complete for the last patient. 

WP9 - Communication and dissemination

  • We congratulate our partner Aqix Ltd on the recent "International Life Sciences Award 2016" received for Best Human Biopsied Tissue Preservative!

WP10 - Management

  • The 2nd COPE amendment has been submitted to the EU Commission which includes the planned project extension until June 2018. We will update you once we hear the outcome of this process.  
  • We have furthermore finished scheduling our next rounds of COPE Management Board calls and have confirmed the date for our COPE Annual Meeting 2017. 
Copyright © 2016  COPE  All rights reserved.
if you would like to unsubscribe from the mailing list, please contact
This project has received funding from the European Union's Seventh Framework Programme for research, technological development and demonstration under grant agreement 305934.

This email was sent to <<Email Address>>
why did I get this?    unsubscribe from this list    update subscription preferences
University of Oxford · Churchill Hospital · Oxford Transplant Centre · Oxford, Oxfordshire OX3 7LE · United Kingdom

Email Marketing Powered by MailChimp